Tocilizumab approved in the US to slow rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD)

Tocilizumab is the first biological therapy to be approved for the treatment of SSc-ILD. The approval was based on data from the Phase III focuSSced trial (n=212) and on supportive data from the Phase II/III faSScinate trial

Source:

Biospace Inc.